Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Differential immunogenicity of homologous versus heterologous boost in Ad26.COV2.S vaccine recipients

19 Jan 2022

Abstract excerpt

BACKGROUND: Protection offered by coronavirus disease 2019 (COVID-19) vaccines wanes over time, requiring an evaluation of different boosting strategies to revert such a trend and enhance the quantity and quality of Spike-specific humoral and cellular immune responses. These immunological parameters in homologous or heterologous vaccination boosts have thus far been studied for mRNA and ChAdOx1 nCoV-19 vaccines,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Animal Virus Infections Studies
Share to COVID-19 Clinical Research Studies
Share to SARS-CoV-2 and COVID-19 Research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 35072129
DOI: 10.1016/j.medj.2021.12.004

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Differential immunogenicity of homologous versus heterologous boost in Ad26.COV2.S vaccine recipientsPMID 35072129Read ↗

Ad26.COV2.S priming provides a solid immunological base for mRNA-based COVID-19 booster vaccinationSemantic proximity Read ↗

Immunogenicity and Reactogenicity of Vaccine Boosters after Ad26.COV2.S PrimingSemantic proximity Read ↗

The Effects of Heterologous Immunization with Prime-Boost COVID-19 Vaccination against SARS-CoV-2Semantic proximity Read ↗

Humoral and cellular immune durability of different COVID-19 vaccine platforms following homologous/heterologous boosters: one-year post vaccinationSemantic proximity Read ↗

Safety, reactogenicity, and immunogenicity of Ad26.COV2.S as homologous or heterologous COVID-19 booster vaccination: Results of a randomized, double-blind, phase 2 trialSemantic proximity Read ↗

Broad anti–SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 vaccinationSemantic proximity Read ↗

Comparative immunogenicity and reactogenicity of heterologous ChAdOx1-nCoV-19-priming and BNT162b2 or mRNA-1273-boosting with homologous COVID-19 vaccine regimensSemantic proximity Read ↗

Heterologous Ad26.COV2.S Prime and mRNA-Based Boost COVID-19 Vaccination Regimens: The SWITCH Trial ProtocolSemantic proximity Read ↗

Immunogenicity and efficacy of Ad26. COV2 .S: An adenoviral vector–based COVID ‐19 vaccineSemantic proximity Read ↗

Interdependencies of cellular and humoral immune responses in heterologous and homologous SARS‐CoV‐2 vaccinationSemantic proximity Read ↗

Hybrid immunity expands the functional humoral footprint of both mRNA and vector-based SARS-CoV-2 vaccinesSemantic proximity Read ↗

BNT162b2-boosted immune responses six months after heterologous or homologous ChAdOx1nCoV-19/BNT162b2 vaccination against COVID-19Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.